IDEAYA Biosciences Inc (IDYA) Investment Analysis
1. Executive Summary
IDEAYA Biosciences Inc (IDYA) is a clinical-stage, oncology-focused precision medicine company committed to the discovery, development, and commercialization of targeted therapeutics.[1, 2] Operating at the interface of synthetic lethality, metabolic and epigenetic dependencies, and antibody-drug conjugates (ADCs), the company designs small molecules and targeted biologics that exploit genetically defined vulnerabilities in cancer cells.[1, 3, 4]
Currently, the company does not have any fully FDA-approved commercial products and generates its revenue entirely through research and development collaborations, licensing upfront payments, and clinical/regulatory milestones from major pharmaceutical partners.[5] The company retains all commercial rights in the United States for its lead program, darovasertib, while its non-U.S. rights are licensed exclusively to French pharmaceutical giant Servier.[6] Consequently, its revenue is geographically split between U.S.-based clinical development and international collaboration inflows.[6]
The company's core pipeline consists of three primary assets under development:
| Core Product Candidate |
Therapeutic Modality |
Primary Target Indication |
Clinical Stage |
Partnership Status |
| Darovasertib [4] |
Oral PKC small molecule inhibitor.[4, 7] |
Primary & Metastatic Uveal Melanoma (UM).[4] |
Phase 2/3 registrational trial (OptimUM-02).[8, 9] |
Retained U.S. rights; ex-U.S. licensed to Servier.[6] |
| IDE397 [10] |
Oral MAT2A small molecule inhibitor.[10, 11] |
MTAP-deleted solid tumors (NSCLC, urothelial).[10, 11] |
Phase 2 clinical trials.[11] |
Wholly-owned; (GSK option waived in 2022).[12] |
| IDE849 [8] |
DLL3-targeting topoisomerase-1 (TOP1) ADC.[8, 13] |
Small cell lung cancer (SCLC), neuroendocrine carcinomas (NEC).[8, 13] |
Phase 1/2 clinical trial.[8, 9] |
Wholly-owned; licensed in from Hengrui Pharma.[14] |
The primary customers for IDEAYA’s research output are global pharmaceutical developers seeking to out-license clinically validated, biomarker-driven oncology programs.[6, 15] Following commercialization, the end customers will be clinical oncologists and genetically pre-screened cancer patient populations.[1, 3] Its key end markets are highly defined clinical sub-segments, notably uveal melanoma (an aggressive, rare form of eye cancer) [16, 17], and MTAP-deleted solid tumors, which represent up to 15% of all human solid tumors.[5]
Clinicians and patients choose IDEAYA’s therapies over historical alternatives due to its strict diagnostic pre-selection strategy.[1, 3] By identifying translational biomarkers prior to treatment, the company’s candidates optimize tumor response rates and avoid the off-target toxicity profiles commonly associated with non-selective, systemic chemotherapies.[1, 3, 18]
2. Business Drivers & Strategic Overview
Product and Service Detail
IDEAYA's economic engine is driven by the clinical translation of precision oncology candidates.[1] The company's lead asset, darovasertib, targets protein kinase C (PKC) mutations that drive primary and metastatic uveal melanoma (UM).[4, 7] Uveal melanoma represents approximately 83% of all ocular melanomas and is characterized by a high rate of metastatic progression, primarily to the liver, where historical prognosis is poor with a median survival of only 4 to 5 months.[16, 19]
IDEAYA is evaluating darovasertib across three distinct settings in UM:
- Metastatic UM (mUM): Under the registrational Phase 2/3 OptimUM-02 trial, darovasertib is combined with crizotinib (a c-MET inhibitor) as a first-line therapy for HLA-A2-negative patients.[8, 9]
- Neoadjuvant UM: The Phase 3 OptimUM-10 trial evaluates darovasertib as a monotherapy designed to shrink primary ocular tumors prior to surgical intervention.[4, 9] This treatment aims to avoid enucleation (surgical eye removal), preserve functional vision, and decrease the required radiation dosage during plaque brachytherapy.[4]
- Adjuvant UM: Partnered with Servier, the Phase 3 OptimUM-11 trial targets high-risk primary UM patients post-treatment to delay or prevent metastatic recurrence, using relapse-free survival (RFS) as its primary endpoint.[4, 20]
The second primary clinical pillar is the metabolic synthetic lethality portfolio, led by the MAT2A inhibitor IDE397.[10, 11] In cells harboring homozygous deletions of the methylthioadenosine phosphorylase (MTAP) gene, the metabolic salvage pathway is disrupted, leaving cancer cells dependent on MAT2A for survival.[21, 22] IDE397 is being advanced as a monotherapy in non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC), and in rational combination studies with IDE892 (its internal, MTA-cooperative PRMT5 inhibitor) and Amgen's PRMT5 inhibitor AMG 193.[11, 20, 22]
Lastly, the company’s antibody-drug conjugate (ADC) platform includes IDE849, a DLL3-targeted TOP1 ADC designed to deliver highly localized genotoxic payloads directly to tumor sites.[8, 13] To maximize the durability of ADC-induced DNA damage, the company is conducting a Phase 1 study combining IDE849 with IDE161, a wholly-owned, potential first-in-class inhibitor of Poly(ADP-ribose) glycohydrolase (PARG).[8, 13]
Moat Analysis
The company is protected by a multi-layered economic and clinical moat driven by regulatory exclusivity, high switching costs, robust intellectual property (IP), and strategic alliances.[4, 6, 7] composition-of-matter patents protect its chemical compounds, including darovasertib and IDE397, through the mid-2030s.[4] These basic IP walls are augmented by regulatory protections; the FDA has granted darovasertib Breakthrough Therapy designation in primary UM, alongside Fast Track and Orphan Drug designations.[7] These designations guarantee accelerated regulatory review and up to seven years of marketing exclusivity post-approval.[7]
Furthermore, the precision medicine model introduces significant clinical switching costs.[1, 3] Once an oncologist pre-screens a patient using molecular diagnostics and matches them to a biomarker-specific therapy like darovasertib, replacing that therapy with general, non-selective systemic chemotherapies is discouraged due to the steep drop-off in efficacy and tolerability.[1, 3, 18]
Ecosystem advantages are also solid. The exclusive license agreement with Servier for darovasertib outside the U.S. provides IDEAYA with $210 million in upfront non-dilutive capital, up to $320 million in regulatory and commercial milestones, and double-digit royalties on ex-U.S. net sales, allowing the company to retain U.S. commercial control while outsourcing the massive global distribution footprint to a well-established partner.[4, 6]
Total Addressable Market (TAM) Analysis
The addressable markets across IDEAYA’s pipeline represent substantial commercial opportunities, supported by epidemiological databases and peak sales estimates:
| Indication / Target Segment |
U.S. Annual Target Population |
Market Value / Peak Sales Forecast |
Source Support |
| Metastatic & Primary Uveal Melanoma (Darovasertib) |
~2,500 annual incident cases in the U.S. (up to 50% develop metastatic disease). |
Peak sales projected between $1.3 Billion and $3.0 Billion. |
DelveInsight [16], UBS [23], Goldman Sachs.[23] |
| MTAP-Deleted Solid Tumors (IDE397) |
~48,000 incident cases in the U.S. across NSCLC & UC; ~14,000 cases in pancreatic cancer. |
Peak sales projected at $1.2 Billion; total market exceeds $5.0 Billion (growing at 14.2% CAGR). |
SEER [24], Mizuho [25], Koala Gains.[5] |
| HRD Solid Tumors (IDE161 / PARG) |
Focused on breast, ovarian, and endometrial cancers with homologous recombination deficiency. |
Overall targeted market exceeds $6.0 Billion (growing at 10.5% CAGR). |
Koala Gains.[5] |
Competitive Landscape
In the uveal melanoma space, darovasertib's primary direct competitor is Immunocore's Kimmtrak (tebentafusp), which was approved in January 2022 as the first T-cell receptor therapeutic for mUM.[26, 27] However, Kimmtrak's clinical utility is limited strictly to HLA-A*02:01-positive patients, which represents only about 40% to 45% of the total uveal melanoma population.[26, 27] This leaves the remaining 55% to 60% HLA-A2-negative patients completely underserved.[27]
IDEAYA's registrational OptimUM-02 trial was designed specifically to target this HLA-A2-negative population, granting the company an uncompetitive, dominant position in this sub-segment.[9, 27] Efficacy data presented at ASCO 2026 confirmed that the darovasertib combination achieved a median PFS of 6.9 months versus 3.1 months for investigator choice therapy, establishing a solid clinical benchmark.[9, 18] Additionally, IDEAYA is expanding clinical trials to target HLA-A2-positive patients (OptimUM-01) and earlier-line neoadjuvant settings (OptimUM-10) where Kimmtrak has no clinical footprint, signaling that the company is actively gaining ground on the incumbent.[4, 28]
In the highly competitive synthetic lethality space, the company's position has been refined by strategic focus.[9] Historically, the company had a broad synthetic lethality partnership with GSK established in 2020, which originally included MAT2A (IDE397), Pol Theta (IDE705), and Werner Helicase (IDE275).[15] GSK waived its option on the MAT2A program in 2022 [12], allowing IDEAYA to retain sole ownership of IDE397.[12] On December 4, 2025, GSK formally terminated the remaining partnership, returning the Werner helicase and Pol-Theta programs back to the company.[12]
Reflecting a strategic narrowing of capital allocation, IDEAYA announced in early 2026 that it would discontinue development of the returned Werner (IDE275) and Pol-Theta (IDE705) programs to prioritize funding for its high-conviction clinical-stage assets, specifically its MAT2A inhibitor (IDE397) and its ADC portfolio (IDE849).[9] This pivot allows the company to hold ground against competitors in the MTAP-deleted space, supported by positive clinical results demonstrating a 39% overall response rate (ORR) for IDE397 in Phase 2 trials.[25]
3. Financial Performance & Valuation
Latest Quarterly Financial Performance (Q1 2026)
IDEAYA reported its fiscal Q1 2026 financial results on May 5, 2026 [1, 9]:
- Collaboration Revenue: Collaboration revenue for the quarter was $6.56 million, down from $10.88 million in Q4 2025.[9] This revenue was recognized under the Servier exclusive license agreement for darovasertib.[9] Standalone quarterly revenue missed the Zacks Consensus Estimate of $18.29 million by 35.62% [29], primarily due to the timing of clinical cost-reimbursement milestone recognitions.[9]
- Operating Expenses: Research and Development (R&D) expenses rose to $95.73 million, up from $86.60 million in Q4 2025, driven by clinical manufacturing and advanced registrational trial activation.[9] General and Administrative (G&A) expenses rose slightly to $19.38 million.[9]
- Net Loss and EPS: Net loss for the quarter widened to $98.54 million, compared to $83.27 million in Q4 2025.[9] Adjusted net loss per share was $1.11, compared to $0.94 in the prior quarter.[9] This missed the Zacks Consensus Estimate of a loss of $1.07 per share by $0.04 (a negative earnings surprise of 3.74%).[29, 30]
- Balance Sheet Liquidity: As of March 31, 2026, the company held cash, cash equivalents, and marketable securities of $972.91 million.[9] Stated cash runway guidance remained unchanged, providing funding into 2030.[9, 28]
Guidance Changes & Key Management Commentary
During the Q1 earnings materials, the company reiterated its long-term cash runway guidance into 2030, confirming that near-term operational spending is fully covered.[9, 28] Important management updates focused on key clinical and executive developments:
- Executive Transition: In February 2026, the company appointed Dr. Theodora (Theo) Ross as Chief Development Officer.[9, 28] Dr. Ross joins from AbbVie, where she served as Vice President and Head of Early Oncology R&D, and will lead early clinical execution and translational strategy.[9, 28]
- FDA Alignments: Management highlighted the successful completion of a Type C meeting with the FDA, aligning on the Phase 3 registrational trial design of OptimUM-11 (adjuvant uveal melanoma, enrolling 450 patients randomized 1:1, primary endpoint relapse-free survival).[4, 20]
- RTOR Filing Timelines: Management confirmed the initiation of the FDA's Real-Time Oncology Review (RTOR) pre-submission process in May 2026, aiming to complete the U.S. accelerated approval NDA filing for darovasertib in first-line HLA-A2-negative mUM in H2 2026.[9]
Subsequent Post-Earnings Events & Stock Price Impact
Historically, IDEAYA's stock price has experienced short-term downward pressure following quarterly financial updates, with an average next-day move of -4.68% across the prior five earnings announcements.[31] However, the Q1 2026 earnings release had a constructive +2.52% next-day move, as investors prioritized clinical timeline visibility over standard, pre-revenue operational losses.[31]
Crucially, the primary valuation driver for the stock occurred shortly after the earnings date. On June 1, 2026, the company presented complete primary analysis data for the OptimUM-02 trial at the ASCO meeting, driving a +7.61% next-day stock surge and adding approximately $195 million to the company's valuation.[32]
Following this clinical validation, the company capitalized on its elevated share price by pricing an underwritten public offering of 7,222,225 shares of common stock and pre-funded warrants for 5,555,576 shares on June 8, 2026, closing on June 10, 2026.[33, 34] This equity offering was priced at $27.00 per share and generated approximately $323.6 million in net proceeds.[34] This raise elevated the company's pro forma cash balance to approximately $1.30 billion, further securing its long-term clinical development trajectory.[7, 34]
Underlying Financial Valuation Drivers
For pre-commercial oncology platforms, traditional backward-looking multiples are less relevant than risk-adjusted Net Present Value (rNPV) of clinical assets and forward-looking sales growth.[5, 35] The fundamental financial drivers investors must monitor include:
- Consensus 5-Year Sales Runway: Driven by darovasertib’s projected launch in 2027 and subsequent ex-U.S. royalty inflows, consensus forward estimates project revenues to scale from $33.99 million in FY 2026 to $116.80 million in FY 2027, and $254.53 million in FY 2028, representing a three-year revenue CAGR of 173.6%.[36]
- Servier Milestone Revenue Recognition: As of March 31, 2026, the company had $155.3 million in remaining performance obligations under the Servier license agreement, which will be recognized as high-margin collaboration revenue over time to support operational expenses.[9]
- Capital Dilution Protection: With $1.30 billion in pro forma cash and a runway into 2030, the company’s capital structure is fully insulated from highly dilutive equity raises prior to its first commercial launch.[28, 34]
4. Risk Assessment & Macroeconomic Considerations
To understand the risk profile of IDEAYA, its corporate vulnerabilities must be mapped by risk category, signaling pathways, and severity:
-------------------> -------------->
(High Severity) (OptimUM-10 / OptimUM-11)
------------------> ---->
(Extreme Severity) (Demands Mature OS Data)
-----------------> [Kimmtrak Expansion/New Entry] ------->
(Moderate Severity) (Immunocore, Delcath, Aura)
Risk Category Matrix
- Company-Specific Execution Risks:
- What Could Go Wrong: The company fails to meet its enrollment targets for registrational trials.[4, 9] Management has already extended the projected timeline for full enrollment of the Phase 3 OptimUM-10 trial (neoadjuvant UM) to the end of 2027 (revised from prior guidance of H1 2027).[9, 28]
- Early Warning Signs: Slow site activation rates or a downward revision of clinical timelines in quarterly business updates.[28]
- Long-Term Thesis Damage: Prolonged delays in neoadjuvant trials postpone or block approval in the eye-preservation setting, which represents a large portion of the long-term TAM.[4, 27]
- Competitive Risks:
- What Could Go Wrong: Direct competitors expand their label indications.[27] Immunocore could initiate clinical trials for Kimmtrak in HLA-A2-negative patients or earlier-line settings, eroding darovasertib's sole ownership of those segments.[27]
- Early Warning Signs: Competitive clinical trial announcements on clinicaltrials.gov or positive cutaneous melanoma readouts from peer pipelines.[26]
- Long-Term Thesis Damage: Loss of sole ownership over the HLA-A2-negative market, forcing price competition and driving gross margins down from target levels of 80% to 90%.[5, 27]
- Customer Concentration or Demand Risks:
- What Could Go Wrong: Over-reliance on Servier for ex-U.S. development and commercialization.[6] If Servier deprioritizes oncology, international execution could stall.[37]
- Early Warning Signs: Strategic restructuring announcements or slow ex-U.S. regulatory filings by Servier.
- Long-Term Thesis Damage: Delayed or impaired international commercial launches, capping ex-U.S. royalty and milestone revenue streams.[6]
- Regulatory or Legal Risks:
- What Could Go Wrong: The FDA rejects the H2 2026 NDA submission for accelerated approval under the RTOR program, demanding mature Overall Survival (OS) data rather than Progression-Free Survival (PFS).[9, 18]
- Early Warning Signs: FDA issuing a Complete Response Letter (CRL) or extending the PDUFA review timeline.
- Long-Term Thesis Damage: Accelerated approval is denied, delaying commercialization by 2 to 3 years while waiting for OS data to mature.[9, 18]
- Balance Sheet / Capital Allocation Risks:
- What Could Go Wrong: Massive clinical cash burn. Despite a strong cash runway, simultaneous advancement of nine clinical programs could accelerate cash depletion.[8, 9]
- Early Warning Signs: Quarterly R&D expenses scaling past $120 million without offsetting milestone payments.
- Long-Term Thesis Damage: The company is forced to execute highly dilutive equity raises at depressed valuations in a weak market environment.[38]
- Industry Structure Risks:
- What Could Go Wrong: The precision medicine landscape shifts toward alternative therapeutic modalities, such as systemic cell therapies (CAR-T) or mRNA-based personalized vaccines, bypassing synthetic lethality small molecules.
- Early Warning Signs: Major peer failures in MAT2A or PRMT5 programs, or sudden shifts in venture capital allocations toward next-gen biologics.
- Long-Term Thesis Damage: Devaluation of the synthetic lethality platform, rendering preclinical assets obsolete before reaching clinical trials.[1]
- Macroeconomic Sensitivities:
- What Could Go Wrong: Sustained high interest rates or inflation. Biotech valuations are highly sensitive to discount rates (WACC).[35] High capital costs depress early-stage biotech valuations.
- Early Warning Signs: Broad sell-off in the XBI (biotech index) or tightening of debt capital markets.
- Long-Term Thesis Damage: Impaired access to capital markets, limiting strategic M&A optionality and partner funding.
5. 5-Year Scenario Analysis
The 5-year scenario analysis estimates the potential valuation of IDEAYA Biosciences in 2031. Pro forma cash is assumed to be $1.30 billion following the June 2026 capital raise.[9, 34] Fully diluted share count is modeled at 105 million to account for pre-funded warrants and standard stock-based compensation dilution.[36, 38]
Base Case (Subjective Probability: 50%)
In the Base Case, darovasertib achieves successful FDA accelerated approval in 2027 and launches in the U.S. in HLA-A2-negative mUM.[9, 18] Servier successfully launches the drug in Europe and international territories, triggering regulatory milestones and steady double-digit royalty inflows.[4, 6] IDE397 finishes Phase 2 trials and moves into registrational trials for MTAP-deleted NSCLC/UC in partnership with a global pharma peer.[10, 24]
- Year 5 Revenue (2031): $704.00 million.
- U.S. Darovasertib Commercial Sales: $450.00 million (representing ~35% market penetration).
- Ex-U.S. Royalties (Servier): $54.00 million (18% average royalty on $300 million ex-U.S. sales).[4, 6]
- Partnered MAT2A (IDE397) Milestones/Sales: $150.00 million.[25]
- Preclinical and Clinical Milestones: $50.00 million.[6]
- Margin/Earnings Assumption: 25% Net Margin (Net Income of $176.00 million).
- Diluted Share Count (2031): 108 million (reflecting minor dilution from SBC).
- Exit Multiple Assumption: 7.0x Price-to-Sales (P/S) exit multiple (typical for commercial precision oncology players with high-growth assets).
- Implied Future Enterprise Value: $4,928.00 million.
- Plus Net Cash (Dilution-Adjusted): $800.00 million (cash burn offset by incoming partner payments).
- Implied 2031 Market Cap: $5,728.00 million.
- Implied 2031 Share Price: $53.04.
- 5-Year Total Return: +41.1% (from current share price of $37.60).[39]
- Annualized Return: +7.1% CAGR.
High Case (Subjective Probability: 30%)
In the High Case, darovasertib emerges as the standard-of-care across all lines of uveal melanoma, capturing significant market share in both HLA-A2-negative and HLA-A2-positive populations, and securing approval in the pre-metastatic neoadjuvant (eye-preservation) setting.[4, 27] Servier achieves block-buster trajectory internationally.[6] Meanwhile, IDE397 secures rapid, priority FDA approval in MTAP-deleted lung and bladder cancers, delivering on its peak sales projection of $1.20 billion.[25]
- Year 5 Revenue (2031): $1,400.00 million.
- U.S. Darovasertib Sales: $800.00 million (rapid neoadjuvant adoption).[4]
- Ex-U.S. Royalties: $100.00 million (20% royalty on $500 million ex-U.S. sales).[4, 6]
- IDE397 Commercial Sales/Milestones: $300.00 million.[25]
- DDR/ADC (IDE849/IDE161) Pipeline Revenue: $100.00 million.[5, 8]
- Regulatory and Commercial Milestones: $100.00 million.[6]
- Margin/Earnings Assumption: 35% Net Margin (Net Income of $490.00 million).
- Diluted Share Count (2031): 102 million (diluted shares reduced due to aggressive share buybacks using commercial cash flows).
- Exit Multiple Assumption: 9.0x P/S exit multiple.
- Implied Future Enterprise Value: $12,600.00 million.
- Plus Net Cash (Dilution-Adjusted): $1,500.00 million (strong free cash flow generation).
- Implied 2031 Market Cap: $14,100.00 million.
- Implied 2031 Share Price: $138.24.
- 5-Year Total Return: +267.7% (from current share price of $37.60).[39]
- Annualized Return: +29.7% CAGR.
Low Case (Subjective Probability: 20%)
In the Low Case, the FDA rejects accelerated approval for darovasertib, requiring a long, multi-year overall survival trial that delays launch until 2030.[9, 18] Servier’s European launch is slow due to reimbursement headwinds.[6] IDE397 fails in Phase 2 due to combination toxicity or lack of durable efficacy, causing the MTAP pipeline to be discontinued.[5, 20]
- Year 5 Revenue (2031): $165.00 million.
- U.S. Darovasertib Sales (Delayed Launch): $150.00 million.
- Ex-U.S. Royalties: $15.00 million (15% royalty on $100 million ex-U.S. sales).[4, 6]
- MAT2A / DDR Pipelines: $0.00 million (failed clinical progression).
- Margin/Earnings Assumption: -10% Net Margin (Operating losses of $16.50 million due to continued R&D restructuring).
- Diluted Share Count (2031): 125 million (highly diluted due to desperate secondary offerings to stay solvent).
- Exit Multiple Assumption: 4.0x P/S exit multiple.
- Implied Future Enterprise Value: $660.00 million.
- Plus Net Cash (Dilution-Adjusted): $200.00 million (cash significantly depleted by clinical failures).
- Implied 2031 Market Cap: $860.00 million.
- Implied 2031 Share Price: $6.88.
- 5-Year Total Return: -81.7% (from current share price of $37.60).[39]
- Annualized Return: -28.9% CAGR.
5-Year Scenario Matrix (USD)
| Scenario |
Revenue / key scale metric in Year 5 |
Margin / earnings assumption |
Valuation multiple assumption |
Current share price |
Implied future share price |
5-year total return |
Annualized return |
Probability |
| High Case |
$1,400.00 million |
35.0% |
9.0x P/S |
$37.60 |
$138.24 |
+267.7% |
+29.7% |
30% |
| Base Case |
$704.00 million |
25.0% |
7.0x P/S |
$37.60 |
$53.04 |
+41.1% |
+7.1% |
50% |
| Low Case |
$165.00 million |
-10.0% |
4.0x P/S |
$37.60 |
$6.88 |
-81.7% |
-28.9% |
20% |
| Weighted |
$705.20 million |
22.5% |
7.0x P/S |
$37.60 |
$69.37 |
+84.5% |
+13.0% |
100% |
Weighted Average 5-Year Price Target: $69.37 (Calculated as: $(0.30 \times 138.24) + (0.50 \times 53.04) + (0.20 \times 6.88) = 41.47 + 26.52 + 1.38 = 69.37$).
ASYMMETRIC GROWTH PROFILE
6. Qualitative Scorecard
Performance Evaluations
- Management Alignment: 8 / 10
- Founder and CEO Yujiro S. Hata has led the company for over 11 years and was recently elected Chairman of the Board, ensuring strategic continuity.[40, 41] He holds direct ownership of ~0.8% of outstanding common shares, representing a meaningful personal commitment to long-term equity growth.[36, 41] Shareholders strongly back executive management, as evidenced by a 64.2 million vote approval in the non-binding advisory Say-on-Pay proposal in June 2026.[40] Options are appropriately utilized as incentive-based equity compensation with multi-year vesting horizons.[42]
- Revenue Quality: 5 / 10
- Currently, revenue is derived entirely from cash licensing, cost-reimbursement, and upfront payments from biopharmaceutical partners, which is inherently volatile and dependent on pipeline execution.[5] However, the credit quality of these revenues is exceptionally high, backed by global players like Servier.[6] This score is poised to improve significantly as darovasertib transitions to high-margin commercial sales post-2027.[5, 9]
- Market Position: 8 / 10
- IDEAYA possesses a dominant position in the HLA-A2-negative uveal melanoma space, representing a clinical monopoly with no direct FDA-approved competitors.[27] While Kimmtrak owns the HLA-A2-positive space, darovasertib’s clinical expansion into that setting plus the neoadjuvant setting positions the company to challenge the incumbent and capture substantial market share.[4, 27]
- Growth Outlook: 9 / 10
- The clinical de-risking of darovasertib’s primary registrational endpoints paves the way for an H2 2026 U.S. NDA filing under the RTOR program.[9, 18] Beyond ocular oncology, the company’s MAT2A and DLL3 ADC programs target multi-billion-dollar opportunities in highly prevalent MTAP-deleted cancers.[5, 24]
- Financial Health: 9 / 10
- With pro forma cash of approximately $1.30 billion post-June 2026 offering and an operating cash runway extending into 2030, IDEAYA’s financial profile is exceptionally robust for a mid-cap biotechnology company.[28, 34] This liquidity removes the overhang of near-term dilutive funding rounds.[38]
- Business Viability: 8 / 10
- The precision medicine oncology model is highly durable.[1] By selecting genetically defined patient populations, the company increases the probability of clinical trial success and reduces systemic toxicities, protecting its pipeline viability against broad-spectrum competitor threats.[1, 3]
- Capital Allocation: 8 / 10
- Management has demonstrated excellent capital discipline.[9, 34] Terminating lower-priority programs (Werner and Pol-Theta helicases) following the GSK deal termination in early 2026 allowed the company to preserve cash for high-conviction clinical combinations.[9] The June 2026 equity raise was executed opportunistically immediately following clinical de-risking.[9, 34]
- Analyst Sentiment: 9 / 10
- Wall Street sentiment is highly positive, with 16 buys, 2 holds, and 0 sells.[43] Strong institutional backing from elite healthcare funds—including FMR, BlackRock, and Baker Bros—reinforces buy-side confidence in the scientific foundation of the pipeline.[44]
- Profitability: 3 / 10
- As a pre-commercial R&D biotechnology entity, the company is deeply unprofitable, posting a GAAP net loss of $98.54 million in Q1 2026.[9] While standard financial models penalize this, the path to commercial profitability is visible post-2027.[9, 36]
- Track Record: 7 / 10
- The company has successfully executed its regulatory milestones, delivering clear Progression-Free Survival (PFS) victories in its primary registrational trial (OptimUM-02) and successfully positioning the pipeline for its first commercial launch.[9, 18]
Overall Blended Score: 7.4 / 10
ROBUST CLINICAL ENGINE
7. Conclusion & Investment Thesis
The fundamental investment thesis for IDEAYA Biosciences is driven by its transition from a speculative, early-stage research platform into a late-stage, regulatory-focused commercial execution story.[2, 27] The primary value-unlock catalyst is the upcoming U.S. NDA submission of darovasertib in HLA-A2-negative mUM in the second half of 2026 under the FDA's RTOR program.[9, 18] This lead program is highly insulated from competitive pressure due to its clinical monopoly in the HLA-A2-negative market sub-segment, which represents 55% to 60% of all uveal melanoma cases where the current standard of care (Kimmtrak) cannot be prescribed.[27]
Beyond darovasertib, the pipeline is supported by the MAT2A platform, where IDE397 has demonstrated strong Phase 2 efficacy (39% ORR) in MTAP-deleted lung and bladder cancers.[25] This target population represents a multi-billion-dollar addressable market with high unmet clinical need.[5, 24] Backed by a pro forma cash balance of approximately $1.30 billion that funds operations into 2030, IDEAYA’s capital structure is shielded from near-term dilutive overhangs.[28, 34] While clinical and regulatory timeline execution remains a key risk, the stock represents a highly favorable risk-reward profile for long-term biotechnology investors.
VALUABLE ONCOLOGY PLATFORM
8. Technical Analysis, Price Action & Short-Term Outlook
IDEAYA’s stock price continues to trade in a sustained technical uptrend, currently valued at approximately $37.65.[36] The stock is trading comfortably above its key support indicators, including its 50-day Simple Moving Average (SMA) of $30.43 and its 200-day SMA of $31.72, signaling robust, institutional accumulation.[36]
Price ($37.65)
^
| / (Technical Uptrend)
| /
|----/----
|---/-----
+----------------------------------> Time
While the June 2026 public offering of common stock at $27.00 created minor, short-term dilution pressure, the rapid technical rebound back toward the $37.00 level reflects strong market appetite and clinical de-risking.[34, 36] Short-term technical indicators, including a Relative Strength Index (RSI) of 63.5, suggest the stock remains in a healthy, non-overbought momentum phase with a positive near-term technical outlook.[45]
TECHNICAL BULLISH OUTLOOK
- SEC Filings - IDEAYA Biosciences - Investor Relations, https://ir.ideayabio.com/sec-filings
- IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors, https://ir.ideayabio.com/2026-06-17-IDEAYA-Biosciences-Announces-Yujiro-S-Hata-Elected-Chairman-of-its-Board-of-Directors
- IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs, https://ir.ideayabio.com/2026-03-18-IDEAYA-Biosciences-Announces-Upcoming-Presentations-at-AACR-2026-Highlighting-Multiple-Clinical-Stage-Pipeline-Programs
- IDEAYA Biosciences (NASDAQ: IDYA) expands cancer pipeline and inks $210M Servier deal - Stock Titan, https://www.stocktitan.net/sec-filings/IDYA/10-k-ideaya-biosciences-inc-files-annual-report-f933f602a00c.html
- IDEAYA Biosciences, Inc. (IDYA) Stock Analysis & Key Metrics | KoalaGains, https://koalagains.com/stocks/NASDAQ/IDYA
- Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - Sep 2, 2025, https://ir.ideayabio.com/2025-09-02-Servier-and-IDEAYA-Biosciences-Partner-to-Bring-Darovasertib,-a-Promising-Uveal-Melanoma-Treatment,-to-Patients-Worldwide
- Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA - BioSpace, https://www.biospace.com/business/servier-commits-up-to-530m-into-eye-cancer-deal-with-ideaya
- IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference, https://ir.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results ..., https://ir.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update
- IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer, https://ir.ideayabio.com/2025-04-10-IDEAYA-Biosciences-Announces-Phase-1-2-Expansion-for-IDE397-and-Trodelvy-R-Combination-in-MTAP-Deletion-Urothelial-Cancer
- IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer - Jul 8, 2024, https://ir.ideayabio.com/2024-07-08-IDEAYA-Announces-Positive-Interim-Phase-2-Monotherapy-Expansion-Data-for-IDE397-a-Potential-First-in-Class-MAT2A-Inhibitor-in-MTAP-Deletion-Urothelial-and-Lung-Cancer
- GSK cuts the cord on Ideaya collaboration, letting go of 2 programs - Fierce Biotech, https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma - Mar 30, 2026, https://ir.ideayabio.com/2026-03-30-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Combination-Study-of-IDE849,-DLL3-TOP1-ADC,-and-IDE161,-PARG-Inhibitor,-in-DLL3-Upregulated-Solid-Tumor-Indications,-including-SCLC,-NETs,-NECs,-and-Melanoma
- IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update, https://ir.ideayabio.com/2026-02-17-IDEAYA-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update
- IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology - PR Newswire, https://www.prnewswire.com/news-releases/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology-301077366.html
- Uveal Melanoma Market Size, Trends and Forecast - DelveInsight, https://www.delveinsight.com/report-store/uveal-melanoma-market
- Uveal melanoma – Basic Information – Overview of Information and Clinical Research, https://clinicaltrials.eu/disease/uveal-melanoma/uveal-melanoma-basic-information/
- IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - Jun 1, 2026, https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO
- Servier and IDEAYA Partner to Develop Darovasertib for Uveal Melanoma | Pienomial, https://www.pienomial.com/clinical-trial-outcomes/servier-and-ideaya-biosciences-partner-to-develop-darovasertib-for-uveal-melanoma
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update, https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario - AACR Journals, https://aacrjournals.org/cancerres/article-pdf/86/7/1558/3753316/can-25-2126.pdf
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers - Jun 15, 2026, https://ir.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers
- Ideaya Biosciences stock 'overlooked', UBS highlights uveal melanoma drug potential, https://www.investing.com/news/company-news/ideaya-biosciences-stock-overlooked-ubs-highlights-uveal-melanoma-drug-potential-93CH-3679560
- IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024, https://ir.ideayabio.com/2024-10-25-IDEAYA-Announces-Positive-Interim-Phase-1-Expansion-Data-of-IDE397-in-MTAP-Deletion-Urothelial-and-Lung-Cancer-as-Late-Breaker-Oral-Presentation-at-EORTC-NCI-AACR-2024
- IDEAYA touts results for MAT2A inhibitor given a pass by GSK | FirstWord Pharma, https://firstwordpharma.com/story/5873515
- Jefferies reiterates Hold on Immunocore stock amid competitor data - Investing.com, https://www.investing.com/news/analyst-ratings/jefferies-reiterates-hold-on-immunocore-stock-amid-competitor-data-93CH-4575714
- IDEAYA and Servier's eye cancer drug heads to FDA after delivering 'best in class' efficacy, https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire, https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update-302762088.html
- IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - May 5, 2026 - Zacks.com, https://www.zacks.com/stock/news/2914440/ideaya-biosciences-inc-idya-reports-q1-loss-misses-revenue-estimates
- What date does IDEAYA Biosciences's (IDYA) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research, https://www.zacks.com/stock/research/IDYA/earnings-calendar
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update, https://www.stocktitan.net/news/IDYA/ideaya-biosciences-reports-first-quarter-2026-financial-results-and-v82d4wgf99p8.html
- IDEAYA Phase 2/3 trial cuts progression risk 58% | IDYA Stock News, https://www.stocktitan.net/news/IDYA/ideaya-biosciences-and-servier-announce-positive-topline-results-knm8u2snyel1.html
- IDEAYA Biosciences $345 million equity offering - Davis Polk, https://www.davispolk.com/experience/ideaya-biosciences-345-million-equity-offering-june-2026
- IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants, https://www.stocktitan.net/sec-filings/IDYA/8-k-ideaya-biosciences-inc-reports-material-event-2cc180650768.html
- IDYA Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/idya/forecast-price-target
- IDEAYA Biosciences, Inc. (IDYA) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/IDYA
- Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide, https://servier.com/en/newsroom/darovasertib-uveal-melanoma-treatment-worldwide/
- IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants - Jun 8, 2026, https://ir.ideayabio.com/2026-06-08-IDEAYA-Announces-Pricing-of-300-Million-Offering-of-Common-Stock-and-Pre-Funded-Warrants
- Ideaya Biosciences Inc USD0.0001 share price | IDYA, https://www.hl.co.uk/shares/shares-search-results/i/ideaya-biosciences-inc-usd0.0001
- Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair, https://www.stocktitan.net/sec-filings/IDYA/8-k-ideaya-biosciences-inc-reports-material-event-7baeda6d2303.html
- IDEAYA Biosciences, Inc. (IDYA) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/management
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4), https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-4w0co5rcobgc.html
- IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential, https://www.directorstalkinterviews.com/ideaya-biosciences-inc-idya-stock-analysis-a-biotech-gem-with-51-upside-potential/4121242570
- IDYA | IDEAYA Biosciences, Inc. Common Institutional Ownership - Quiver Quantitative, https://www.quiverquant.com/stock/IDYA/institutions/
- IDYA Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/ideaya-biosciences-inc-technical